Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMV-12
- Development stage
- Phase 2
- Lead developer
- Hongyi Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LMV-12 (also known as HE003) is an orally administered small molecule drug under clinical development for the treatment of advanced solid tumors, including non-small cell lung cancer and renal cell carcinoma. It acts as a dual inhibitor targeting both VEGFR2 (vascular endothelial growth factor receptor 2) and c-Met (hepatocyte growth factor receptor), functioning as a VEGFR2 antagonist and c-Met inhibitor. By blocking these pathways, LMV-12 aims to inhibit tumor angiogenesis and proliferation. The drug was initially developed by Nanchang Hongyi Pharmaceutical Co., Ltd., with ongoing clinical trials evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced or metastatic malignancies[1][6].
- Other names
- HE003HE-003HE 003
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on LMV-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMV-12.